CAPR logo

CAPRICOR THERAPEUTICS INC

CAPRNASDAQ
πŸ† #3070 by market capUS Equity
$3.93β–² $0.08 (+2.08%)
πŸŒ… Pre-market$3.94β–² 0.22%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 2.1%
7dβ–² 0.3%
14dβ–Ό 40.1%
30dβ–Ό 80.9%
1yβ–Ό 50.9%
🏦Market Cap
$228M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
16.9%
Healthy
βš–οΈP/S Ratio
10.0x
Elevated
Otter Score
50
Weak

Trading Snapshot

Day Range
$3.87 – $3.98
52-Week Range
$2.96 – $40.37
Volume
$2.91B
Avg Volume
$3.63B
Shares Outstanding
57.9M
Next Earnings
Sep 6, 2026

Fundamentals Snapshot

Annual Revenue
$23M
Last Q Revenue
$6M
P/E Ratio
β€”
P/S Ratio
10.0x
EPS (TTM)
$-2.31
Dividend Yield
β€”

Why Investors Own CAPR

  • βœ“High-growth profile β€” revenue up -9.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 75% gross margin and 18% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$23Mβ–Ό βˆ’8.6% YoY
Gross Margin (TTM)
75.4%β–² +2.6% YoY
Operating Income (TTM)
$6Mβ–Ό βˆ’8.6% YoY
Free Cash Flow (TTM)
$4Mβ–Ό βˆ’8.6% YoY

About CAPRICOR THERAPEUTICS INC

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (β€œDMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
50/100

Analyst Ratings

β“˜
Consensus
Hold
15 analysts
Strong Buy0
Buy0
Hold12
Sell1
Strong Sell2
Ratings as of Aug 2026

Latest News & Updates